Lilly publishes new clinical trial data on early breast cancer, mantle cell lymphoma

On Friday, Eli Lilly Co. LLY published new clinical trial data on treatments for certain types of early breast cancer and mantle cell lymphoma. New analysis from a late-stage trial of Verzenio in node-positive, high-risk early breast cancer showed that the treatment, in combination with endocrine therapy, improved invasive disease-free survival rates by 5.9 in adults 65 and older and 6.4% in patients under 65. The data also demonstrate that the treatment's durable efficacy is maintained when dose reductions are necessary, the company said. Updated data from a study of Jaypirca in patients with covalent BTK inhibitor pre-treated relapsed or refractory mantle cell lymphoma showed that efficacy and safety were consistent with previously reported results, Lilly said. The data will be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Friday. Lilly shares are up 0.4% premarket and have risen 19.3% in the year to date, compared to a 9.9 percent gain for the S&P 500.